Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
- William Blair has initiated coverage on Denali Therapeutics Inc DNLI, a company focused on developing drugs for neurodegenerative diseases.
- 01/03/2025
|
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
- Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
- 12/09/2024
|
Denali Starts Dosing in Phase II Parkinson's Disease Study
- DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
- 12/06/2024
|
Denali Has A Neurodegenerative Edge Despite Market Skepticism
- Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts without immediate need for additional funding. Denali's pipeline targets critical neurodegenerative pathways, with promising candidates for lysosomal storage disorders, Parkinson's disease, and neuroinflammation.
- 11/16/2024
|
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
- DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
- 11/08/2024
|
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.
- 11/06/2024
|
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/29/2024
|
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
- Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 09/16/2024
|
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
- DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
- 09/04/2024
|
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
- SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to filing a biologics license application (BLA) for accelerated approval and subsequent conversion to full approval for tividenofusp alfa (DNL310) for the treatment of MPS II (Hunter syndrome). Agreement was reached that cerebrospinal fluid heparan sulfate (CSF HS) is reasonably likely to predict clinical benefit and can be used as a surrogate endpoint to support accelerated approval for tividenofusp alfa in MPS II. Based on discussions with CDER, Denali will include preclinical and clinical data on biomarkers (CSF HS and neurofilament light (NfL)) and safety in the BLA for tividenofusp alfa as a treatment of MPS II and intends to submit the BLA under the accelerated approval pathway in early 2025.
- 09/03/2024
|
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
- Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company's $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline.
- 08/19/2024
|
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
- SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced publication of nonclinical data in the August 14, 2024 issue of Science Translational Medicine (link) demonstrating the ability of the Oligonucleotide Transport Vehicle (OTV) platform to achieve broad biodistribution of antisense oligonucleotides (ASOs) in the central nervous system (CNS) and skeletal and cardiac muscle following intravenous (IV) administration.
- 08/14/2024
|
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
- The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 08/06/2024
|
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
- 08/01/2024
|
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
- Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 07/23/2024
|
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
- The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
- 07/08/2024
|
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
- Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
- 06/28/2024
|
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
- Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/24/2024
|
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
- Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
- 06/06/2024
|
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
- Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
- 06/04/2024
|
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
- SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. DNL126 is an investigational enzyme replacement therapy designed to cross the BBB for the potential treatment of MPS IIIA (Sanfilippo syndrome type A).
- 06/03/2024
|
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
- Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024.
- 05/13/2024
|
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
- Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
- 05/08/2024
|
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
- 05/07/2024
|
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial , which evaluates Denali's eIF2B agonist DNL343.
- 05/01/2024
|
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
- Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/09/2024
|
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
- Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
- 03/28/2024
|
To the Moon and Beyond: 7 Stocks With Cosmic Potential
- Stocks with moonshot potential are drawing attention amidst the current bullishness in the stock market. Despite the latest inflation reports pointing to a potential delay in the Federal Reserve's interest-rate cuts, the investing sentiment remains optimistic.
- 03/14/2024
|
Denali: Leveraging Transport Vehicle Technology For Neurological Gains
- Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly.
- 03/06/2024
|
Top 3 Wall Street stock picks for March
- While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by major indices such as the S&P 500 and the Dow Jones Industrial Average (DJIA) which have been running close to record highs with generally favorable forecasts.
- 03/06/2024
|
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
- Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
- 02/28/2024
|
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.
- 02/27/2024
|
Denali Therapeutics Announces $500 million Private Placement Equity Financing
- SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. The pre-funded warrants will have an exercise price of $0.01 per share of common stock, be immediately exercisable, and remain exercisable until exercised in full. Denali anticipates the gross proceeds from the PIPE to be approximately $500 million. The financing is expected to close on February 29, 2024, subject to customary closing conditions. Proceeds from the financing are expected to be used to support Denali's ongoing research and development activities, the acceleration and expansion of its proprietary BBB-crossing Transport Vehicle (TV) technology, as well as general corporate purposes and working capital.
- 02/27/2024
|
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
- The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings.
- 02/08/2024
|
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its BBB-crossing enzyme replacement therapies in development for the treatment of mucopolysaccharidoses (MPS). New clinical data on tividenofusp alfa (DNL310) in MPS II (Hunter syndrome) and mouse model data on DNL126 (ETV:SGSH) in MPS IIIA (Sanfilippo syndrome type A) are being presented this week at the 20th Annual WORLDSymposium™ in San Diego, California.
- 02/07/2024
|
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at the 20th Annual WORLDSymposium™, which will be held February 4-9, 2024, in San Diego, California.
- 02/01/2024
|
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
- Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.
- 01/26/2024
|
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced program progress and expected milestones for 2024, which Chief Executive Officer, Ryan Watts, Ph.D., will highlight during a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. Pacific Time.
- 01/08/2024
|
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
- Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer — that perception is pure fiction.
- 01/02/2024
|
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
- Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
- 12/22/2023
|
Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?
- The consensus price target hints at a 123.4% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 12/21/2023
|
Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?
- The consensus price target hints at a 163.8% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/27/2023
|
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
- Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.84 per share a year ago.
- 11/07/2023
|
Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in Denali Therapeutics Inc. (DNLI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 11/06/2023
|
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?
- Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
- 09/07/2023
|
Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues
- Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.
- 08/10/2023
|
Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates
- Denali Therapeutics Inc. (DNLI) came out with quarterly earnings of $1.30 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.48 per share a year ago.
- 08/08/2023
|
MPS II And Beyond: Implications Of Denali's Promising Pipeline
- Denali Therapeutics is a promising underdog in the biotech sector, focusing on neurodegenerative diseases, with significant investments in scientific exploration and a robust financial health despite net losses. The company's pipeline includes seven clinical development programs, with four predicted to advance into clinical trials for diseases such as Parkinson's, Alzheimer's, and ALS, and interim results showing promising reductions in key biomarkers of neurodegeneration. Despite challenges such as effective drug delivery and potential side effects, Denali's innovative products and research methodologies set it apart from competitors, making it a compelling investment option.
- 07/23/2023
|
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
- Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson's unique strategy to delay aging. This has investors trying to sniff out which biotech stocks to buy.
- 06/29/2023
|
Denali (DNLI) Provides Update on Hunter Syndrome Study
- Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).
- 06/21/2023
|
Why Shares of Denali Therapeutics Are Up Monday
- Denali released first-quarter earnings last week. The company focuses on therapies to treat neurodegenerative diseases and has a relatively deep pipeline.
- 05/15/2023
|
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
- Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
- 05/09/2023
|
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
- Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.53 per share a year ago.
- 05/08/2023
|
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?
- Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
- 03/29/2023
|
Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
- Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.
- 02/28/2023
|
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
3 More Mid-Cap Biotechs The Street Sees Doubling
- Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the lives of millions of patients with a wide range of diseases.
- 02/22/2023
|
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
- Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 02/03/2023
|
Denali: Need Patient Data To Justify That High Valuation
- Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash.
- 01/16/2023
|
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
- Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.
- 11/04/2022
|
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
- The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
- 11/02/2022
|
Denali Therapeutics: Two Shots On Goal For Parkinson's Disease Treatment
- Denali Therapeutics initiated a phase 3 study, using BIIB122 for the treatment of Parkinson's Disease patients with the pathogenic mutation of LRRK2, in October of 2022. The company initiated a phase 2b study, using BIIB122 for the treatment of early-stage Parkinson's Disease patients, in May of 2022.
- 10/28/2022
|
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
- Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/29/2022
|
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?
- Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
- 09/07/2022
|
3 Companies Growing Revenue Fast
- S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past five years through Aug. 9.
- 08/10/2022
|
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
- Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
- 08/09/2022
|
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/25/2022
|
7 F-Rated Stocks to Avoid During the Downturn
- It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers. The post 7 F-Rated Stocks to Avoid During the Downturn appeared first on InvestorPlace.
- 03/23/2022
|
Denali Therapeutics Inc. (DNLI) Moves 7.5% Higher: Will This Strength Last?
- Denali Therapeutics Inc. (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 03/21/2022
|
Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study
- Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.
- 03/10/2022
|
Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag
- Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.
- 03/01/2022
|
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Misses Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -51.22% and 67.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
12 biotech stocks to consider buying now as prospects for the sector brighten this year
- Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double
- 02/06/2022
|
Why Denali Therapeutics Stock Is Sinking This Week
- The FDA placed a hold on the company's planned clinical trial of an experimental Alzheimer's disease drug.
- 01/13/2022
|
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
- Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
- 11/08/2021
|
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Misses Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.29% and -78.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
New Strong Sell Stocks for October 12th
- ONEM, DNLI, FMC, GPL, and LGO have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2021.
- 10/12/2021
|
Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)
- SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced positive Phase 1 clinical results and regulatory progress for two investigational small molecule therapeutics in development for the treatment of amyotrophic lateral sclerosis (ALS) at the 2021 Annual Northeast ALS (NEALS) Meeting being held virtually, October 6-7.
- 10/06/2021
|
Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting
- SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced upcoming presentations at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting being held virtually, October 6-7.
- 09/29/2021
|
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
- Proven commercial leader with broad global experience in building and running commercial organizations and successfully launching products for people with neurological and rare diseases Proven commercial leader with broad global experience in building and running commercial organizations and successfully launching products for people with neurological and rare diseases
- 09/27/2021
|
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
- — Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS — — Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —
- 09/09/2021
|
President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
- Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Watts sold 18,333 shares of Denali Therapeutics at a price of $54.59 per share.
- 09/03/2021
|
Biotech Takeovers Moved at Snail's Pace in 2nd Quarter
- Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be the most expensive of the pair with a market cap of $6.4 billion, while Clovis is far more digestible with a market value of only $567 million.
- 08/30/2021
|
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
- Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denali's Transport Vehicle to cross the blood-brain barrier Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denali's Transport Vehicle to cross the blood-brain barrier
- 08/26/2021
|
Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know
- Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2021
|
Why Denali Therapeutics Stock Is Sinking Today
- The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.
- 07/26/2021
|
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
- SOUTH SAN FRANCISCO, Calif., July 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced additional positive interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II). The interim results being presented today at MPS 2021, the 16th International Symposium on MPS and Related Diseases, include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively, 6-month biomarker data from Cohort A and up to 3-month biomarker data from Cohort B. Denali Management will host a webinar today for analysts and investors beginning at approximately 11:30 a.m. Eastern Time.
- 07/25/2021
|
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021
- Management to host webinar for analysts and investors on July 25th Management to host webinar for analysts and investors on July 25th
- 07/15/2021
|
Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?
- Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- 06/15/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
- Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
- 05/04/2021
|
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights.
- 05/03/2021
|
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson's Disease
- SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced final results from Phase 1 and Phase 1b studies of its small molecule LRRK2 inhibitor, BIIB122/DNL151, which is being developed in collaboration with Biogen as a potential treatment of Parkinson's disease. Safety and biomarker goals were met in both studies, supporting plans to advance BIIB122/DNL151 into late-stage clinical development in Parkinson's disease by year-end 2021. The results will be presented at the International Association of Parkinsonism and Related Disorders Virtual Congress, being held May 1-4.
- 05/01/2021
|
Denali Therapeutics Inc. (DNLI) Down 12.3% Since Last Earnings Report: Can It Rebound?
- Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
- 03/27/2021
|
Denali Is Getting To Be More And More Interesting
- Denali released some early positive data. Meanwhile its market cap has reduced by 25%.
- 03/25/2021
|
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
- If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines appeared first on InvestorPlace.
- 03/12/2021
|
Why Denali Therapeutics Stock Popped Today
- The biotech received good news from the FDA concerning one of its pipeline candidates.
- 03/11/2021
|
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)
- SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). DNL310, Denali's lead investigational brain-penetrant enzyme replacement therapy, is under evaluation in a Phase 1/2 study in patients with Hunter syndrome as a potential treatment for both central nervous system (CNS) and peripheral manifestations of the disease.
- 03/11/2021
|
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
- Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/18/2021
|
Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)
- SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced additional positive interim results from the ongoing Phase 1/2 study evaluating ETV:IDS (DNL310) as a potential brain-penetrant enzyme replacement therapy for treating both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II). The data will be presented later today during a late-breaker session at WORLDSymposium™. Denali management will host an analyst webinar today beginning at 8:00 a.m. Eastern Time to discuss both interim clinical and new preclinical data that will be presented at the conference.
- 02/12/2021
|
F-star Therapeutics: New Biologics Platform For Immunotherapy
- F-star Therapeutics: New Biologics Platform For Immunotherapy
- 01/21/2021
|
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
- SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Nancy Thornberry has joined the Board of Directors, effective January 8, 2021. Ms. Thornberry's extensive biotech leadership and pharmaceutical experience includes more than 30 years of development and discovery work in multiple disease areas, including diabetes and endocrinology.
- 01/11/2021
|
Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration
- SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced program progress and expected milestones for 2021, which Chief Executive Officer, Ryan Watts, Ph.D., will highlight during a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, at 10 a.m. Eastern Time.
- 01/08/2021
|
Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today
- 2020 is almost over. Maybe it's time to cash in -- and cash out?
- 12/23/2020
|
5 Medical Outperformers That Might Lose Steam in 2021
- Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
- 12/22/2020
|
7 Biotech Stocks To Buy Beyond Covid Vaccine Plays
- It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
- 12/14/2020
|
3 Best Biotech Stocks to Buy in November
- While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.
- 11/18/2020
|
Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)
- SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced biomarker proof of concept was achieved for its Transport Vehicle (TV) technology in a Phase 1/2 study of ETV:IDS (DNL310) for the potential treatment of Hunter syndrome (MPS II). Denali's TV platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the BBB after intravenous administration.
- 11/10/2020
|
Denali Therapeutics (DNLI) Investor Presentation - Slideshow
- The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event..
- 09/14/2020
|
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
- Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.
- 08/25/2020
|
Denali Is Flush With Cash After Partnership With Biogen
- Denali Therapeutics struck a deal with Biogen for its LRRK2 inhibitor program earlier this month that resulted in the company receiving over $1 billion in cash.
- 08/19/2020
|
Loss-Making Denali Therapeutics Inc. (NASDAQ:DNLI) Set To Breakeven
- Denali Therapeutics Inc. (NASDAQ:DNLI) is possibly approaching a major achievement in its business, so we would like...
- 08/18/2020
|
Genomic Medicine: Summer 2020 Update
- FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
- 08/13/2020
|
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
- BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's COVID-19 vaccine in China.
- 08/09/2020
|
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 8.20% and 57.60%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/07/2020
|
Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights. “We are thrilled with the strong progress across our pipeline, the continued productivity across the company despite the current situation imposed by the COVID-19 pandemic, and a new collaboration with Biogen on our LRRK2 program for Parkinson’s disease patients and certain TV-enabled programs,” said Ryan Watts, Ph.D., CEO. “I am particularly excited that our first therapeutic candidate leveraging our proprietary blood-brain barrier crossing TV technology platform has entered clinical studies in patients. We believe the TV platform could transform the treatment of neurological disease.”Second Quarter 2020 and Recent Business Highlights * Entered into a Collaboration Agreement with Biogen on LRRK2 program for Parkinson’s disease and certain transport vehicle (“TV”) platform-enabled programs for neurodegenerative diseases \- In August 2020, Denali entered into a binding agreement with Biogen to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (“LRRK2”) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali’s TV technology platform to cross the BBB. Under the terms of the agreement, Biogen will make an upfront payment to Denali of $560 million and make a $465 million equity investment in Denali from the purchase of 13.3 million newly issued shares of Denali common stock at approximately $34.94 per share, representing 11.2 percent of Denali’s pro-forma outstanding stock. Should the LRRK2 program achieve certain development and commercial milestones, Denali will be eligible to receive up to $1.125 billion in potential milestone payments. In the LRRK2 collaboration, Biogen and Denali will share responsibility and costs for global development (60 percent Biogen; 40 percent Denali), and will share responsibility and costs as well as profits and losses for commercialization in the U.S. (50 percent Biogen; 50 percent Denali) and China (60 percent Biogen; 40 percent Denali). Outside the U.S. and China, Biogen will be responsible for commercialization and pay Denali tiered royalties. The transaction is expected to close after satisfaction of requirements under applicable antitrust laws and other customary closing conditions, and with respect to the collaboration, execution of a definitive collaboration agreement. * Selected DNL151 to advance into late stage clinical studies in Parkinson’s disease patients \- In August 2020, Denali announced that DNL151 has been selected to progress into late stage clinical studies in Parkinson’s disease patients with a kinase activating mutation in LRRK2 and in sporadic Parkinson’s disease patients. Patient enrollment is expected to commence in 2021. * Commenced dosing of DNL310 in Hunter syndrome patients \- In August 2020, Denali commenced dosing of its ETV:IDS biotherapeutic (DNL310) enabled by its TV platform technology in a Phase 1/2 Hunter syndrome clinical study. DNL310 is an intravenously administered recombinant form of the iduronate 2-sulfatase (“IDS”) enzyme engineered to cross the BBB using Denali’s TV technology. It is intended to treat overall clinical manifestations of Hunter syndrome, including cognitive and behavioral function, which are not adequately addressed by current standard of care. * Publication of two scientific papers describing blood-brain barrier transport vehicle delivery technology \- In May 2020, Denali announced the publication of two new papers describing its BBB delivery technology in Science Translational Medicine. The first paper describes the invention of Denali’s TV technology and demonstrates its ability to successfully deliver therapeutic antibodies to the brain at levels sufficient for robust effects. The second paper focuses on the application of the TV technology for lysosomal storage disease by delivering enzymes across the BBB resulting in the normalization of biomarkers in a disease model of Hunter syndrome. * RIPK1 CNS program update \- In June 2020, together with partner Sanofi, Denali announced results from Phase 1b clinical studies with small molecule RIPK1 inhibitor DNL747 in Alzheimer’s disease and ALS. Denali and Sanofi have paused DNL747 and switched to DNL788, with plans to initiate a clinical study around year-end 2020. * RIPK1 peripheral program update \- In July 2020, Denali announced that partner Sanofi has commenced dosing of DNL758, a peripherally-restricted small molecule inhibitor of RIPK1, in a Phase 1b clinical study in hospitalized adult patients with severe COVID-19 lung disease. Prior to this, Sanofi successfully completed the Phase 1 healthy volunteer study with DNL758, which appears well tolerated at doses tested. Further clinical studies in multiple indications are being planned by Sanofi. * Leadership promotion \- In June 2020, Denali appointed Joe Lewcock, Ph.D. as Chief Scientific Officer. Dr. Lewcock had previously served as Senior Vice President of Biology Discovery. * COVID-19 response update \- To address risks posed by the COVID-19 pandemic, Denali has implemented policies that enable some of its employees to work remotely. For all on-site personnel, Denali has implemented several safety protocols, including regular, mandatory COVID-19 testing procedures and compliance measures for social distancing and use of personal protective equipment. After initial COVID-19 pandemic shutdown restrictions were put in place in March 2020, Denali experienced a pause in patient recruitment in several clinical trials. Recruitment has since resumed for all affected clinical trials.Second Quarter 2020 Financial ResultsFor the three months ended June 30, 2020, Denali reported a net loss of $58.8 million compared with a net loss of $58.3 million for the three months ended June 30, 2019.Collaboration revenue was $5.8 million for the three months ended June 30, 2020, compared to $4.2 million for the three months ended June 30, 2019. The increase of $1.6 million in collaboration revenue was primarily due to a $4.8 million increase in revenue recognized under the Takeda Collaboration Agreement, partially offset by a $3.2 million decrease in revenue recognized under the Sanofi Collaboration Agreement.Total research and development expenses were $53.2 million for the three months ended June 30, 2020, compared to $51.9 million for the three months ended June 30, 2019. The increase of approximately $1.3 million was primarily due to an increase in personnel-related expenses, including stock-based compensation, attributable to an increase in Denali’s research and development headcount and new equity award grants. Additionally, there were increases in external expenses related to progression of Denali’s portfolio, including the ETV:IDS and EIF2B programs due to the progress of these programs in the clinic. These increases were partially offset by decreases in the LRRK2 platform associated expenses, reflecting completion of the DNL201 clinical activities and slowdown of DNL151 clinical activities in the three months ended June 30, 2020 as a result of COVID-19, and certain other TV platform and other research and development expenses.General and administrative expenses were $14.0 million for the three months ended June 30, 2020 compared to $15.1 million for the three months ended June 30, 2019. The decrease of approximately $1.1 million was primarily attributable to a decrease in personnel-related expenses, including stock-based compensation, primarily driven by lower stock-based compensation expense related to certain performance and market-based awards, partially offset by increases in professional services costs.Cash, cash equivalents, and marketable securities were $556.8 million as of June 30, 2020.About Denali TherapeuticsDenali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali’s progress and business plans; expectations regarding the proposed transaction with Biogen, including all financial aspects of the collaboration and equity investment; the potential benefits and results of the proposed transaction with Biogen; the anticipated completion of the Biogen transaction; plans to conduct clinical development activities and commercialize products; LRRK2 inhibitors as modifying therapy for Parkinson’s disease; plans, timelines and expectations related to DNL151, DNL310 and Denali’s TV technology; plans, timelines and expectations related to DNL747, DNL788 and DNL758 of both Denali and Sanofi; and statements made by Denali’s Chief Executive Officer.
- 08/07/2020
|
Illumina Revenue Decline, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:ILMN)
- Illumina stock tumbles as quarterly numbers decline. Roche stumbles on Phase III Tecentriq update.
- 08/07/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
Biogen, Denali Announce Billion-Dollar Collaboration On Parkinson's Treatment
- Biogen and Denali Therapeutics early Thursday announced a billion-dollar collaboration to move forward on testing on a Denali treatment for Parkinson's disease, sending DNLI stock soaring.
- 08/06/2020
|
Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration
- Shares of Denali Therapeutics Inc. rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc. announced a $465 million equity investment as part of a collaboration on Denali's treatment for Parkinson's disease. Biogen's stock was little changed ahead of the open. Under terms of the collaboration, Biogen will make an upfront payment of $560 million, as well as the equity investment from the purchase of 13.3 million newly issued shares, representing about 11% of the shares outstanding, at $34.94 per share, which is 50% above Wednesday's closing price of $23.24. Denali will also be eligible to receive up to $1.125 billion in potential milestone payments depending on the achievement of certain development and commercial milestones. Biogen and Denali will co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's, and Biogen will receive exclusive options to license two preclinical programs from Denali's transport vehicle (TV) technology platform. Denali's stock, which was on track to open above the June 3 record close of $28.82, has rallied 33.4% year to date through Wednesday, while Biogen shares have lost 6.9% and the S&P 500 has gained 3.0%.
- 08/06/2020
|
Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients
- * DNL151 selected to advance into two late stage studies in Parkinson’s disease in patients with a kinase activating mutation in LRRK2 and in patients with sporadic disease * Denali and collaboration partner Biogen are finalizing DNL151 clinical development plans and intend to commence patient enrollment in 2021SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for treatment of neurodegenerative diseases, today announced that DNL151 has been selected to progress into late stage studies in Parkinson’s disease patients with a kinase activating mutation in LRRK2 and in sporadic Parkinson’s disease patients.“Safety and biomarker data from studies of our two LRRK2 molecules in Parkinson’s patients support moving DNL151 into late stage clinical studies with the aim of addressing the devastating clinical decline and pathology of disease in Parkinson’s patients," said Carole Ho, M.D., Chief Medical Officer. “Our collaboration partner Biogen is a respected leader in neurodegenerative diseases and brings deep scientific and development expertise in Parkinson’s disease which will allow us to accelerate our development plan and we believe increase the likelihood of ultimate success.”LRRK2 is a regulator of lysosomal function, which is impaired in Parkinson’s disease and may be restored by LRRK2 inhibition. Inhibition of LRRK2 activity may slow the progression of Parkinson’s disease in patients with and without known genetic risks based on restoration of lysosomal function. Mutations in the LRRK2 gene can cause Parkinson’s disease and are a major driver of lysosomal dysfunction, which contributes to neurodegeneration.DNL151 has completed dosing of 162 healthy volunteers in an ongoing Phase 1 clinical study and 25 Parkinson’s patients in a Phase 1b clinical study. Denali is currently completing further dose escalation cohorts in an expanded Phase 1 and an additional cohort in the Phase 1b study to define the full therapeutic window of the molecule. Based on the clinical data to date that have been generated in Europe, DNL151 appears to have an acceptable safety and tolerability profile, and has met desired target engagement goals. An Investigational New Drug application for DNL151 was cleared by the U.S. Food and Drug Administration in July 2020 and enables expansion of our clinical studies for DNL151 globally. Based on the totality of preclinical and clinical data to date, both DNL201 and DNL151 (two chemically distinct LRRK2 inhibitors) have met Denali’s requirements to proceed into further late stage clinical studies. However, Denali has selected DNL151 due to pharmacokinetic properties that provide additional dosing regimen flexibility.Denali and Biogen are working to finalize the clinical development plans for the LRRK2 program and intend to commence two separate Parkinson’s disease studies, one in patients with a kinase activating mutation in LRRK2 and the other in patients with sporadic disease. Patient enrollment is expected to commence in 2021.About Denali’s LRRK2 programDenali has two CNS-penetrant small molecules that inhibit LRRK2 in clinical studies, DNL201 and DNL151.DNL 201 has successfully completed a Phase 1 study in 122 healthy volunteer subjects and a Phase 1b study in 28 Parkinson’s disease patients. DNL201 has been generally safe and well tolerated in doses tested and met all target engagement and biomarker goals. Based on this, DNL201 has met the bar for progression into further clinical studies.DNL151 has successfully completed dosing of 162 healthy volunteers in an ongoing Phase 1 study in healthy volunteer subjects and completed dosing in 25 Parkinson’s disease patients in a Phase 1b clinical study. DNL151 met safety, target engagement and biomarker goals in the Phase 1 healthy volunteer study. Denali is currently completing further dose escalation cohorts in an expanded Phase 1 and Phase 1b study to define the full therapeutic window. Target and pathway engagement of greater than 50 percent and a dose-dependent reduction of BMP in urine of up to 50 percent were observed at clinically relevant doses in healthy volunteers. The DNL151 Phase 1b study (NCT04056689) in Parkinson’s disease patients is a 28-day, multicenter, randomized, placebo controlled, double-blind clinical trial in patients with mild-to-moderate Parkinson’s disease being conducted in the U.S. and Europe. Its purpose is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, including target and pathway engagement biomarkers as well as certain exploratory clinical endpoints, after multiple oral doses of DNL151. To date, 25 patients have been enrolled in the study, and the protocol has been amended to expand the study with up to 10 additional patients. Both the Phase 1 healthy volunteer and Phase 1b Parkinson’s patient studies are anticipated to complete in 2020.Further information on clinical studies with DNL151, DNL201 and Denali’s efforts in Parkinson’s disease can be found on clinicaltrials.gov and EngageParkinsons.com – Denali’s Parkinson’s disease patient engagement website for patients, caregivers and healthcare professionals.About DenaliDenali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the BBB for neurodegenerative diseases. Denali Therapeutics pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali Therapeutics is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com. Cautionary Note Regarding Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, plans, timelines and expectations related to DNL 201, DNL151 and other LRRK2 inhibitor molecules; expectations regarding the proposed collaboration with Biogen; the potential benefits and results of Denali’s collaboration agreement with Biogen; expectations regarding the commencement of, and timing of patient enrollment in, clinical trials; expectations regarding the timing of completion of ongoing clinical trials; and statements made by Denali’s Chief Medical Officer.Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: any and all risks to Denali’s business and operations caused directly or indirectly by the evolving COVID-19 pandemic; the risks that the proposed transaction with Biogen may not be completed in a timely manner or at all; the possibility that certain closing conditions to the proposed transaction with Biogen will not be satisfied, including the finalization of a definitive collaboration agreement; risks related to obtaining the requisite regulatory approvals, including those required under antitrust laws; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of the agreements with Biogen (including without limitation the failure to timely obtain requisite regulatory approvals); Denali’s early stages of clinical drug development; Denali’s and its partners’ ability to complete the development and, if approved, commercialization of its product candidates; Denali’s and its partners’ ability to enroll patients in clinical trials; Denali’s reliance on third parties for the manufacture and supply its product candidates for clinical trials; Denali’s dependence on successful development of its BBB platform technology; Denali’s and its partners’ ability to conduct or complete clinical trials on expected timelines; the risk that preclinical profiles of Denali’s product candidates, such as DNL151, may not translate in clinical trials and that such product candidates may not sufficiently modify Parkinson’s disease; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali’s ability to continue to create a pipeline of product candidates or develop commercially successful products; developments relating to Denali’s competitors and its industry, including competing product candidates and therapies; Denali’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali’s strategic plans for its business, product candidates and BBB platform technology; Denali’s ability to obtain additional capital to finance its operations, as needed; Denali’s ability to accurately forecast future financial results in the current environment; general economic and market conditions; and other risks and uncertainties, including those described in Denali’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and Denali’s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. Denali disclaims any obligation to update any forward-looking statements, except as required by law.Contacts: Morgan Warners (202) 295-0124 mwarners@gpg.comorLizzie Hyland (646) 495-2706 lhyland@gpg.com
- 08/06/2020
|
Why Shares of Denali Therapeutics Are Skyrocketing
- Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease...
- 08/06/2020
|
Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients
- * Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19 * DNL758, discovered by Denali and partnered with Sanofi, is a small molecule inhibitor of RIPK1 that does not cross the blood-brain barrier, and is being developed for patients with peripheral inflammatory diseasesSOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing of DNL758, a peripherally-restricted small molecule inhibitor of RIPK1, in a Phase 1b study in hospitalized adult patients with severe COVID-19 lung disease.RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. The scientific rationale in treating severe COVID-19 with a RIPK1 inhibitor compound is to attenuate the exaggerated immune response to the SARS-CoV-2 viral infection and thereby limit potential tissue damage resulting from excessive inflammation and aim to improve patient recovery.“We know that inhibition of RIPK1, a known target in the TNF-pathway, can significantly modulate the body’s immune response," said Ryan Watts, Ph.D., CEO. “Our partner Sanofi is expanding its clinical investigation of DNL758 into patients with severe COVID-19. We are proud to stand with Sanofi in this effort, with the aim to contribute solutions in the fight against this terrible pandemic.”Denali and Sanofi entered a broad partnership in October 2018 for the global development and commercialization of RIPK1 inhibitors. Beyond COVID-19, the partners are currently investigating DNL788 for CNS indications and DNL758 for peripheral inflammatory indications. Sanofi is responsible for the development and commercialization of DNL758, and covers all costs related to DNL758, and Denali is entitled to receive development and sales milestone payments and royalties on product sales.Further information on the Phase 1b clinical study with DNL758/SAR443122 for COVID-19 (study number NCT04469621) can be accessed on the ClinicalTrials.gov website or by clicking here.About DenaliDenali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases. Denali Therapeutics pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali Therapeutics is based in South San Francisco. For additional information, please visit http://www.denalitherapeutics.com/. Cautionary Note Regarding Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, plans, timelines and expectations related to DNL758 by both Denali and Sanofi; expectations regarding the dosing of DNL758 in a Phase 1b study in hospitalized adult patients with severe COVID-19 lung disease and potential results; and statements made by Denali’s Chief Executive Officer.Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: any and all risks to Denali’s business and operations caused directly or indirectly by the evolving COVID-19 pandemic; Denali’s early stages of clinical drug development; Denali’s and its partners’ ability to complete the development and, if approved, commercialization of its product candidates; Denali’s and its partners’ ability to enroll patients in its ongoing and future clinical trials; Denali’s reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of the Sanofi collaboration agreement; Denali’s dependence on successful development of its BBB platform technology; Denali’s and its partners’ ability to conduct or complete clinical trials on expected timelines; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali’s ability to continue to create a pipeline of product candidates or develop commercially successful products; Denali’s ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali’s strategic plans for its business, product candidates and blood-brain barrier platform technology; and other risks and uncertainties, including those described in Denali’s most recent Annual Report on Form 10-K, most recent Quarterly Report on From 10-Q and Denali’s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. Denali disclaims any obligation to update any forward-looking statements, except as required by law.Denali Contact Morgan Warners (202) 295-0124 mwarners@gpg.comSanofi Contact Ashleigh Koss (908) 981-8745 Ashleigh.Koss@sanofi.com
- 07/29/2020
|
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/28/2020
|
NFL star Bobby Wagner joining former Microsoft, Amazon execs in Seattle-based tech fund
- The Seattle Seahawks linebacker will join investment firm Fuse Venture Partners to assist early-stage e-commerce companies.
- 07/28/2020
|
Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Hold at BidaskClub
- BidaskClub cut shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, BidAskClub reports. Other equities research analysts have also recently issued reports about the stock. Nomura reissued a buy rating and issued a $35.00 price target on shares of Denali Therapeutics […]
- 07/18/2020
|
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes therapeutic messages into the genome to treat diseases at their source.
- 07/07/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Given Average Rating of “Buy” by Analysts
- Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been given an average rating of “Buy” by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price target among […]
- 07/05/2020
|
Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI)
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/28/2020
|
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Zacks Investment Research
- Denali Therapeutics (NASDAQ:DNLI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports. According to Zacks, “Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s […]
- 06/24/2020
|
Dow Sheds Nearly 7% as Pullback Finally Arrives
- Stocks Analysis by Zacks Investment Research covering: SPDR S&P 500, Union Pacific Corporation, KeyCorp, CarMax Inc. Read Zacks Investment Research's latest article on Investing.com
- 06/12/2020
|
Sanofi and Denali Halt Clinical Trials of Alzheimer Drug
- The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.
- 06/10/2020
|
Denali Drops 7% In After-Market On Halt Of DNL747 Drug Study
- Denali Therapeutics Inc. (DNLI) announced that it is pausing clinical studies of DNL747, its neurological drug candidate for the treatment of Alzheimer’s disease and ALS, sending shares down some 7% in after-market trading on Tuesday.The stock dropped almost 7% to $23.95 in late market trading after the biotech company said that the decision was made following results from Phase 1b studies of the small molecule RIPK1 inhibitor DNL747 in Alzheimer's disease and amyotrophic lateral sclerosis (ALS).The study was conducted in partnership with Sanofi (SNYNF) to develop small molecule inhibitors of the RIPK1 enzyme, a new class of potential therapeutic agents for a range of neurological and inflammatory diseases, including ALS.The data demonstrated “emerging evidence that higher levels of target inhibition may be required for maximizing efficacy, and challenges to achieving higher doses imposed by molecule-specific toxicity findings with DNL747”.“Together with our partner Sanofi, we have decided to pause clinical studies with DNL747 and focus our efforts on accelerating development of DNL788, which we believe has superior drug properties and a more rapid path toward proof-of-concept clinical studies in patients in multiple neurological indications," said Denali CEO Ryan Watts.RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.Denali reported that data from the completed Phase 1 study with peripherally-restricted RIPK1 inhibitor DNL758 in healthy patients display an encouraging profile, as the molecule appears safe and tolerable at doses tested. Denali partner Sanofi is in charge of the development of DNL758 and is currently planning further clinical studies in multiple indications based on successful Phase 1 data.Investors have been enthusiastic about Denali, pushing shares up 56% so far this year to trade at $25.71 as of Tuesday’s close.Earlier this month, five-star analyst Andrew Fein at H.C. Wainwright reiterated a Buy rating on the stock with a $28 price target, saying that Denali’s blood brain pressure barrier (BBB) transport vehicle platform, which leverages receptor-mediated transcytosis (RMT) as a noninvasive strategy for enhancing brain exposure of biotherapeutics, can present a broad future value driver for the company.Denali scores 5 Buys from Wall Street analysts adding up the Strong Buy consensus for the stock. With an average price target of $27.60, analysts still expect shares to add a moderate 7.3% over the coming 12 months. (See Denali stock analysis on TipRanks).Related News: Sorrento’s COVID-19 Cocktail Could Drive Major Upside, Says Analyst Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine Global Blood Therapeutics Up On Expanded Use Plans For Sickle Cell Treatment More recent articles from Smarter Analyst: * Boeing (BA) Stock Probably Rallied Too Far, Too Fast * Latam Airlines' Shares Could Be Heading Further South; Top Analyst Says 'Sell' * Starbucks’ (SBUX) Road to Recovery Will Take Longer Than Anticipated, Says Analyst * TripAdvisor: Post Pandemic, Many Challenges Await
- 06/10/2020
|
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
- Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to.
- 06/09/2020
|
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today
- 06/08/2020
|
New research offers hope for a way through the blood-brain barrier
- A duo of preclinical studies recently demonstrated a new way to ferry medicines past the blood-brain barrier. And other research is on the way.
- 06/01/2020
|
Venture Funding of Drug Startups Down, But Not Out
- Fourteen biotechs have gone public in 2020, just three fewer than for the same period last year Continue reading...
- 05/28/2020
|
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
- 05/28/2020
|
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
- Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with.
- 05/27/2020
|
What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock
- Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 05/21/2020
|
Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report
- Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...
- 05/10/2020
|
Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates
- Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/08/2020
|
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
- SOUTH SAN FRANCISCO, May 07, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross.
- 05/07/2020
|
Analysts Estimate Denali Therapeutics Inc.
(DNLI) to Report a Decline in Earnings: What to Look Out for
- Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2020
|
Denali Therapeutics (NASDAQ:DNLI) Lowered to Buy at ValuEngine
- Denali Therapeutics (NASDAQ:DNLI) was downgraded by investment analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday, ValuEngine reports. Several other research firms also recently issued reports on DNLI. Cantor Fitzgerald restated a “neutral” rating on shares of Denali Therapeutics in a report on Wednesday, March […]
- 05/02/2020
|
Does The Denali Therapeutics Inc. (NASDAQ:DNLI) Share Price Fall With The Market?
- If you're interested in Denali Therapeutics Inc. (NASDAQ:DNLI), then you might want to consider its beta (a measure of...
- 05/01/2020
|
Bank of America Corp DE Sells 18,580 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
- Bank of America Corp DE cut its holdings in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 42.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,044 shares of the company’s stock after selling 18,580 shares during the period. Bank of […]
- 04/30/2020
|
Denali Therapeutics (NASDAQ:DNLI) Trading 5% Higher
- Denali Therapeutics Inc (NASDAQ:DNLI)’s stock price traded up 5% on Friday . The stock traded as high as $22.92 and last traded at $22.77, 272,489 shares traded hands during trading. A decline of 60% from the average session volume of 682,172 shares. The stock had previously closed at $21.68. Several equities analysts have recently weighed […]
- 04/26/2020
|
Analysts Anticipate Denali Therapeutics Inc (NASDAQ:DNLI) Will Post Quarterly Sales of $5.93 Million
- Analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to announce $5.93 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Denali Therapeutics’ earnings. The lowest sales estimate is $4.00 million and the highest is $13.50 million. Denali Therapeutics posted sales of $4.21 million in the same quarter last year, which suggests […]
- 04/26/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Short Interest Down 5.9% in March
- Denali Therapeutics Inc (NASDAQ:DNLI) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 8,910,000 shares, a decrease of 5.9% from the March 15th total of 9,469,800 shares. Currently, 12.4% of the company’s stock are sold short. Based on an average […]
- 04/24/2020
|
Head-To-Head Contrast: BIONDVAX PHARMA/S (NASDAQ:BVXV) vs. Denali Therapeutics (NASDAQ:DNLI)
- BIONDVAX PHARMA/S (NASDAQ:BVXV) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends. Volatility and Risk BIONDVAX PHARMA/S has a beta of 1.33, suggesting that its stock price is […]
- 04/20/2020
|
Were Hedge Funds Right About Edgewell Personal Care Company (EPC)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/18/2020
|
Were Hedge Funds Right About Park National Corporation (PRK)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/18/2020
|
Were Hedge Funds Right About Core Laboratories N.V. (CLB)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/18/2020
|
Were Hedge Funds Right About Mobile Mini Inc (MINI)?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/18/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Shares Sold by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. lowered its position in Denali Therapeutics Inc (NASDAQ:DNLI) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,787 shares of the company’s stock after selling 3,300 shares during the period. Goldman Sachs Group Inc. […]
- 04/16/2020
|
Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock?
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 04/15/2020
|
Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
- In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics (DNLI), with a price target of $28.00. The
- 04/15/2020
|
Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
- In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Denali Therapeutics (
DNLI
–
Research Report
), with a price target of
$28.00
. The company’s shares closed last Wednesday at $20.04.
According to
TipRanks.co
- 04/15/2020
|
Bank of New York Mellon Corp Reduces Stock Position in Denali Therapeutics Inc (NASDAQ:DNLI)
- Bank of New York Mellon Corp reduced its position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 336,230 shares of the company’s stock after selling 2,687 shares during the period. Bank of […]
- 04/15/2020
|
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
- Sean McCarthy, president and CEO of CytomX Therapeutics Inc.
- 04/09/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Shares Sold by AQR Capital Management LLC
- AQR Capital Management LLC trimmed its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 28.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,205 shares of the company’s stock after selling 19,789 shares during the period. AQR Capital Management LLC’s holdings in Denali Therapeutics were […]
- 04/09/2020
|
Don’t Ignore The Fact That This Insider Just Sold Some Shares In Denali Therapeutics Inc. (NASDAQ:DNLI)
- We note that the Denali Therapeutics Inc. (NASDAQ:DNLI) Co-Founder, Ryan Watts, recently sold US$94k worth of stock...
- 04/04/2020
|
Ryan J. Watts Sells 4,807 Shares of Denali Therapeutics Inc (NASDAQ:DNLI) Stock
- Denali Therapeutics Inc (NASDAQ:DNLI) CEO Ryan J. Watts sold 4,807 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $19.48, for a total value of $93,640.36. Following the sale, the chief executive officer now directly owns 22,013 shares in the company, […]
- 04/04/2020
|
Credit Suisse AG Sells 5,894 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
- Credit Suisse AG cut its holdings in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 12.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,004 shares of the company’s stock after selling 5,894 shares during the period. Credit Suisse AG’s holdings […]
- 04/04/2020
|
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by ValuEngine
- Denali Therapeutics (NASDAQ:DNLI) was upgraded by ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Thursday, ValuEngine reports. DNLI has been the subject of several other reports. Nomura restated a “buy” rating and set a $35.00 target price on shares of Denali Therapeutics in a research note on Monday, March […]
- 04/04/2020
|
Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Hold at Zacks Investment Research
- Denali Therapeutics (NASDAQ:DNLI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. According to Zacks, “Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic […]
- 04/04/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ
- 04/03/2020
|
Denali Therapeutics (NASDAQ:DNLI) Rating Increased to Buy at Zacks Investment Research
- Zacks Investment Research upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $21.00 price objective on the stock. According to Zacks, “Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development […]
- 04/03/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Expected to Announce Quarterly Sales of $5.93 Million
- Equities research analysts predict that Denali Therapeutics Inc (NASDAQ:DNLI) will report sales of $5.93 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Denali Therapeutics’ earnings, with the lowest sales estimate coming in at $4.00 million and the highest estimate coming in at $13.50 million. Denali Therapeutics reported […]
- 04/03/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 2)
BELLUS Health Inc (NASDAQ:...
- 04/03/2020
|
BRIEF-Denali Therapeutics Says Paused Enrollment in Phase 1, Phase 1B Trials Due To Covid-19
- Denali Therapeutics Inc:
- 04/02/2020
|
Still more COVID-19 actions - healthcare
- Molina Healthcare (NYSE:MOH) is providing virtual urgent care to Marketplace members vis its partnership with Teladoc (NYSE:TDOC) and is expanding Teladoc to all Medicare and Medicaid members. It is c
- 04/02/2020
|
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
- “In these unprecedented times, our resolve to defeat degeneration is undiminished and our top priority is to ensure the health and safety of our employees, community, partners and clinical trial participants,” said Ryan Watts, Ph.D., CEO. For the ongoing DNL151 Phase 1 and Phase 1b trials, enrollment of additional healthy volunteers and patients at higher doses has been paused due to the COVID-19 pandemic. Denali is analyzing available data from these trials and is on track to select either DNL201 or DNL151 by mid-2020 to progress into Phase 2/3 trials.
- 04/02/2020
|
Alexander O. Schuth Sells 1,427 Shares of Denali Therapeutics Inc (NASDAQ:DNLI) Stock
- Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 1,427 shares of the company’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $19.49, for a total transaction of $27,812.23. Following the completion of the sale, the chief operating officer now directly owns 28,662 shares of the […]
- 04/02/2020
|
Insider Selling: Denali Therapeutics Inc (NASDAQ:DNLI) CFO Sells 1,428 Shares of Stock
- Denali Therapeutics Inc (NASDAQ:DNLI) CFO Steve E. Krognes sold 1,428 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $19.48, for a total value of $27,817.44. Following the sale, the chief financial officer now owns 1,006,488 shares in the company, valued at […]
- 04/02/2020
|
Great West Life Assurance Co. Can Makes New $104,000 Investment in Denali Therapeutics Inc (NASDAQ:DNLI)
- Great West Life Assurance Co. Can acquired a new position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,044 shares of the company’s stock, valued at approximately $104,000. Other institutional investors also recently […]
- 03/30/2020
|
Bamco Inc. NY Sells 31,705 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
- Bamco Inc. NY reduced its position in Denali Therapeutics Inc (NASDAQ:DNLI) by 3.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 952,957 shares of the company’s stock after selling 31,705 shares during the period. Bamco Inc. NY’s holdings in Denali Therapeutics were worth $16,601,000 at the end of the most recent reporting period. Several […]
- 03/27/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Receives Average Recommendation of "Buy" from Analysts
- Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have earned a consensus recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokers that have […]
- 03/27/2020
|
Algert Global LLC Makes New $540,000 Investment in Denali Therapeutics Inc (NASDAQ:DNLI)
- Algert Global LLC purchased a new position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 30,974 shares of the company’s stock, valued at approximately $540,000. Other large investors also recently bought and sold shares […]
- 03/26/2020
|
Analyzing Denali Therapeutics (NASDAQ:DNLI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI)
- Denali Therapeutics (NASDAQ:DNLI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Insider & Institutional Ownership 67.1% of Denali Therapeutics shares are owned by institutional investors. […]
- 03/26/2020
|
Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund
- Repertoire Immune Medicines, a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat
- 03/25/2020
|
Citigroup Inc. Sells 60,995 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
- Citigroup Inc. reduced its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 77.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,522 shares of the company’s stock after selling 60,995 shares during the quarter. Citigroup Inc.’s holdings in Denali Therapeutics were worth $305,000 at […]
- 03/24/2020
|
Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Buy at ValuEngine
- Denali Therapeutics (NASDAQ:DNLI) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Friday, ValuEngine reports. Several other research analysts have also weighed in on DNLI. Nomura reissued a “buy” rating and set a $35.00 price objective on shares of Denali Therapeutics in a report […]
- 03/22/2020
|
Denali Therapeutics (NASDAQ:DNLI) Rating Reiterated by Cantor Fitzgerald
- Cantor Fitzgerald reaffirmed their neutral rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a report published on Wednesday morning, Zacks.com reports. DNLI has been the topic of several other reports. Goldman Sachs Group upgraded shares of Denali Therapeutics from a neutral rating to a buy rating and boosted their price objective for the stock from […]
- 03/22/2020
|
Denali Therapeutics (NASDAQ:DNLI) Upgraded to Hold by BidaskClub
- Denali Therapeutics (NASDAQ:DNLI) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports. A number of other research analysts also recently issued reports on DNLI. Goldman Sachs Group raised shares of Denali Therapeutics from a “neutral” rating to a […]
- 03/20/2020
|
Denali Therapeutics (NASDAQ:DNLI) Rating Increased to Outperform at Evercore ISI
- Evercore ISI upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from an in-line rating to an outperform rating in a research report sent to investors on Friday morning, Briefing.com Automated Import reports. The firm currently has $20.00 price target on the stock. Other analysts have also issued research reports about the company. BidaskClub lowered Denali Therapeutics from […]
- 03/16/2020
|
Goldman sees 143% upside in Amarin in premarket analyst action
- IDEAYA Biosciences (NASDAQ:IDYA) initiated with Buy rating and $12 (192% upside) price target at Roth Capital.Menlo Therapeutics (NASDAQ:MNLO) resumed with Overweight rating and $15 (466% upside) at C
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
The Dow Jones Industrial Average Just Had Its Worst Day Since 1987. Yes, You Can Call It Panic.
- The Dow Jones Industrial Average tumbled 2353 points, or 10%, on Thursday, its worst drop since 1987, and some Treasuries fell too.
- 03/12/2020
|
Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer
- Flagship Pioneering, a life sciences innovation enterprise, announced the launch of Repertoire Immune Medicines, a clinical-stage biotechnology compan
- 03/12/2020
|
Charles Schwab Investment Management Inc. Has $6.52 Million Holdings in Denali Therapeutics Inc (NASDAQ:DNLI)
- Charles Schwab Investment Management Inc. raised its holdings in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 374,478 shares of the company’s stock after purchasing an additional 7,203 shares during the period. […]
- 03/12/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Shares Purchased by Barclays PLC
- Barclays PLC lifted its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,668 shares of the company’s stock after purchasing an additional 4,218 shares during the period. Barclays PLC owned about […]
- 03/12/2020
|
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Reaffirmed by Nomura
- Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “buy” rating reissued by equities research analysts at Nomura in a report released on Monday, AnalystRatings.com reports. They presently have a $35.00 price objective on the stock. Nomura’s price objective indicates a potential upside of 94.55% from the stock’s current price. Other research analysts have also issued research reports […]
- 03/11/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Expected to Post Quarterly Sales of $5.93 Million
- Wall Street analysts expect that Denali Therapeutics Inc (NASDAQ:DNLI) will announce $5.93 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Denali Therapeutics’ earnings, with the lowest sales estimate coming in at $4.00 million and the highest estimate coming in at $13.50 million. Denali Therapeutics posted sales of […]
- 03/10/2020
|
Comparing Repligen (NASDAQ:RGEN) and Denali Therapeutics (NASDAQ:DNLI)
- Repligen (NASDAQ:RGEN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation. Risk and Volatility Repligen has a beta of 1.34, indicating that its share price is 34% more […]
- 03/10/2020
|
Nomura Maintains Their Buy Rating on Denali Therapeutics (DNLI)
- Nomura analyst Christopher Marai maintained a Buy rating on Denali Therapeutics (DNLI) on March 4 and set a price target of $35.00. The company's shares
- 03/09/2020
|
Nomura Maintains Their Buy Rating on Denali Therapeutics (DNLI)
- Nomura analyst
Christopher Marai
maintained a
Buy
rating on Denali Therapeutics (
DNLI
–
Research Report
) on March 4 and set a price target of
$35.00
. The company’s shares closed last Monday at $17.68.
According to
TipRanks.com
, Marai is a 3-star
- 03/09/2020
|
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Zacks Investment Research
- Zacks Investment Research downgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, “Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s […]
- 03/07/2020
|
Denali Therapeutics (NASDAQ:DNLI) Lifted to Strong-Buy at ValuEngine
- Denali Therapeutics (NASDAQ:DNLI) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued on Tuesday, ValuEngine reports. Other analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set […]
- 03/03/2020
|
Denali Therapeutics (DNLI) Gets a Buy Rating from H.C. Wainwright
- H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Denali Therapeutics (DNLI) today and set a price target of $28.00. The company's shares
- 03/02/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from Brokerages
- Denali Therapeutics Inc (NASDAQ:DNLI) has received a consensus recommendation of “Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average 1-year target […]
- 03/02/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Major Shareholder Sells $78,868,971.00 in Stock
- Denali Therapeutics Inc (NASDAQ:DNLI) major shareholder Douglas K. Bratton sold 3,894,764 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $20.25, for a total value of $78,868,971.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which […]
- 03/02/2020
|
Financial Review: Axcella Health (NASDAQ:AXLA) and Denali Therapeutics (NASDAQ:DNLI)
- Axcella Health (NASDAQ:AXLA) and Denali Therapeutics (NASDAQ:DNLI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends. Institutional and Insider Ownership 63.3% of Axcella Health shares are held by institutional investors. Comparatively, […]
- 03/01/2020
|
BidaskClub Downgrades Denali Therapeutics (NASDAQ:DNLI) to Sell
- BidaskClub downgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a sell rating in a report released on Wednesday, BidAskClub reports. DNLI has been the subject of a number of other research reports. HC Wainwright reissued a buy rating and issued a $28.00 target price on shares of Denali Therapeutics in a report […]
- 03/01/2020
|
Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates
- It's been a mediocre week for Denali Therapeutics Inc. (NASDAQ:DNLI) shareholders, with the stock dropping 19% to...
- 02/29/2020
|
Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates
- There's been a notable change in appetite for Denali Therapeutics Inc. (NASDAQ:DNLI) shares in the week since its...
- 02/29/2020
|
First Allied Advisory Services Inc. Buys 3,000 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
- First Allied Advisory Services Inc. lifted its stake in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 15.8% in the 4th quarter, Holdings Channel reports. The fund owned 21,950 shares of the company’s stock after acquiring an additional 3,000 shares during the quarter. First Allied Advisory Services Inc.’s holdings in Denali Therapeutics were worth $380,000 as […]
- 02/29/2020
|
Research Analysts Issue Forecasts for Denali Therapeutics Inc's FY2019 Earnings (NASDAQ:DNLI)
- Denali Therapeutics Inc (NASDAQ:DNLI) – Equities research analysts at Jefferies Financial Group issued their FY2019 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Monday, February 24th. Jefferies Financial Group analyst M. Yee expects that the company will earn ($2.13) per share for the year. Jefferies Financial Group […]
- 02/29/2020
|
Denali Therapeutics (NASDAQ:DNLI) Upgraded to Buy at ValuEngine
- Denali Therapeutics (NASDAQ:DNLI) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Wednesday, ValuEngine reports. Several other research firms have also issued reports on DNLI. BidaskClub lowered Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. […]
- 02/28/2020
|
Denali Therapeutics (NASDAQ:DNLI) Shares Down 12.1%
- Denali Therapeutics Inc (NASDAQ:DNLI)’s share price fell 12.1% on Thursday . The company traded as low as $19.01 and last traded at $19.02, 1,097,060 shares traded hands during trading. An increase of 40% from the average session volume of 781,543 shares. The stock had previously closed at $21.63. A number of brokerages recently weighed in […]
- 02/28/2020
|
BRIEF-Denali Therapeutics Inc Posts Qtrly Loss Per Share Of $0.56
- Denali Therapeutics Inc:
- 02/27/2020
|
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2020
|
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates
- Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -5.66% and -70.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2020
|
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered.
- 02/27/2020
|
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
- SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad...
- 02/27/2020
|
Denali Therapeutics (DNLI) - Analysts' Weekly Ratings Changes
- A number of firms have modified their ratings and price targets on shares of Denali Therapeutics (NASDAQ: DNLI) recently: 2/26/2020 – Denali Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 2/26/2020 – Denali Therapeutics was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating. […]
- 02/27/2020
|
Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated at Jefferies Financial Group
- Equities researchers at Jefferies Financial Group began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a report issued on Monday, Marketbeat reports. The firm set a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 58.51% from the company’s current price. Other equities […]
- 02/26/2020
|
Denali Therapeutics (NASDAQ:DNLI) Downgraded by BidaskClub to "Sell"
- Denali Therapeutics (NASDAQ:DNLI) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, BidAskClub reports. DNLI has been the subject of several other reports. Stifel Nicolaus initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, February […]
- 02/26/2020
|
Head-To-Head Comparison: Orchard Therapeutics (NASDAQ:ORTX) and Denali Therapeutics (NASDAQ:DNLI)
- Orchard Therapeutics (NASDAQ:ORTX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings. Profitability This table compares Orchard Therapeutics and Denali Therapeutics’ net margins, return on equity and return […]
- 02/26/2020
|
Could Denali Therapeutics Inc.’s (NASDAQ:DNLI) Investor Composition Influence The Stock Price?
- Every investor in Denali Therapeutics Inc. (NASDAQ:DNLI) should be aware of the most powerful shareholder groups...
- 02/25/2020
|
Jefferies starts Denali Therapeutics at Buy ahead of 'lots of catalysts in 2020' DNLI;SNY;BIIB
- Jefferies starts Denali Therapeutics at Buy ahead of 'lots of catalysts in 2020' Jefferies DNLI SNY BIIB
- 02/24/2020
|
Brokerages Anticipate Denali Therapeutics Inc (NASDAQ:DNLI) Will Announce Earnings of -$0.49 Per Share
- Equities research analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to announce earnings of ($0.49) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Denali Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.14). Denali Therapeutics posted earnings per share of […]
- 02/21/2020
|
Stifel likes Alector and Denali in premarket analyst action
- Alector (NASDAQ:ALEC) initiated with Buy rating and $44 (52% upside) price target at Stifel.Aridis Pharmaceuticals (NASDAQ:ARDS) initiated with Buy rating and $18 (193% upside) price target at Roth Ca
- 02/19/2020
|
Three Expensive Biotech Stocks To Avoid
- Tesla's stock is often criticized as overpriced. These three biotechs are way more expensive.
- 02/17/2020
|
3 Stocks That Are Way More Expensive Than Tesla
- 3 Stocks That Are Way More Expensive Than Tesla, Stocks: TSLA,ADVM,FIXX,FTSV,IMMU,DNLI,TELL, release date:Feb 17, 2020
- 02/17/2020
|
Denali Therapeutics chief medical officer sets a cultural standard
- Chief Medical Officer and Head of Development Company: Denali Therapeutics HQ: South San Francisco Years at company: 5 Career turning point: Switching from clinical medicine to research and moving into a management role at Genentech Advice: Women need to be very intentional with networking, Ho says. “I always encourage people to not apologize for the things they do outside of work, be proud of them, talk about them at work and incorporate them into your work life balance.” Carole Ho’s wending career path to biotech startup Denali Therapeutics brought big risks — and big rewards. In 2002, she had just finished her residency in neurology at Massachusetts General Hospital and Brigham and Women’s Hospital for Harvard Medical School when she decided to chance it all and move west to work in a lab at Stanford University.
- 02/14/2020
|
Denali Therapeutics Inc. (DNLI) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 02/14/2020
|
Denali Therapeutics Inc. (DNLI) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 02/14/2020
|
Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?
- Is (DNLI) Outperforming Other Medical Stocks This Year?
- 02/07/2020
|
Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year?
- Is (DNLI) Outperforming Other Medical Stocks This Year?
- 02/07/2020
|
Denali Therapeutics Inc (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Analysts
- Denali Therapeutics Inc (NASDAQ:DNLI) has received an average recommendation of “Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among brokers that have issued a […]
- 02/06/2020
|
Wedbush Weighs in on Denali Therapeutics Inc's Q1 2020 Earnings (NASDAQ:DNLI)
- Denali Therapeutics Inc (NASDAQ:DNLI) – Wedbush upped their Q1 2020 earnings estimates for Denali Therapeutics in a report released on Wednesday, January 29th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.62) for the quarter, up from their prior estimate of ($0.65). Wedbush also issued estimates for Denali […]
- 02/04/2020
|
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
- Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
- 02/03/2020
|
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
- Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
- 02/03/2020
|
Denali Therapeutics (NASDAQ:DNLI) Downgraded to Hold at ValuEngine
- ValuEngine downgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report released on Tuesday morning, ValuEngine reports. A number of other equities research analysts also recently weighed in on DNLI. HC Wainwright reiterated a buy rating and issued a $28.00 price target on shares of Denali Therapeutics […]
- 02/01/2020
|
Head to Head Analysis: Denali Therapeutics (NASDAQ:DNLI) & Amgen (NASDAQ:AMGN)
- Denali Therapeutics (NASDAQ:DNLI) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk. Earnings & Valuation This table compares Denali Therapeutics and Amgen’s top-line revenue, earnings per share and valuation. […]
- 02/01/2020
|
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000.
- 02/01/2020
|
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized...
- 02/01/2020
|
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
- Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- 01/31/2020
|
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
- Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- 01/31/2020
|
Moving Average Crossover Alert: Denali Therapeutics
- Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 01/31/2020
|
Moving Average Crossover Alert: Denali Therapeutics
- Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 01/31/2020
|
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
- Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
- 01/30/2020
|
Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35%
- Once again, the world is gripped by uncertainty. Fear of an international outbreak of coronavirus, on top of recent worrisome developments between the US and Iran, have spooked investors, sending all three major indexes down over the last week. However, no matter the global outlook, one thing remains certain; investors are still in the game, on the lookout for the best opportunities the market presents. As it happens, if you know where to look, a world teetering precariously on the edge often presents specific investment opportunities. With this in mind, we pulled up two of Goldman Sachs’ recent stock picks which the renowned investment bank thinks can soar in the coming months. Using TipRanks’ Stock Comparison tool, we were able to read the fine print on what 2020 has in store for the two tickers. Let’s take a closer look. Denali Therapeutics Inc. ( DNLI ) Denali Therapeutics has started off 2020 with a bang. The neurodegenerative disease-focused biotech is up by 34 % year-to-date. The reason for the surge?
- 01/30/2020
|
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
- Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
- 01/30/2020
|
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
- Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
- 01/30/2020
|
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
- Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
- 01/29/2020
|
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
- Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.
- 01/29/2020
|
The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...
- 01/29/2020
|
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Goldman Sachs Group
- Goldman Sachs Group upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a neutral rating to a buy rating in a report published on Sunday, BenzingaRatingsTable reports. Goldman Sachs Group currently has $37.00 price target on the stock, up from their prior price target of $20.00. Several other brokerages also recently issued reports on DNLI. HC Wainwright […]
- 01/29/2020
|
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
- Denali Therapeutics Inc. (DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the shares are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,173,913 shares of its common stock.
- 01/29/2020
|
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
- SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten...
- 01/29/2020
|
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
- AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
- 01/28/2020
|
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
- AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
- 01/28/2020
|
AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study
- AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
- 01/28/2020
|
7 Big Biotech Stocks to Avoid
- The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list. Here's why.
- 01/28/2020
|
IFR US ECM Calendar
- NEW YORK, Jan 28 (IFR) -
- 01/28/2020
|
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, ...
- 01/28/2020
|
Analysts' Downgrades for January, 28th (ABBV, ACHC, ALGN, AMAT, ARGKF, ARWR, ATRC, ATVI, BGNE, BPFH)
- Analysts’ downgrades for Tuesday, January 28th: AbbVie (NYSE:ABBV) was downgraded by analysts at ValuEngine from a hold rating to a sell rating. Acadia Healthcare (NASDAQ:ACHC) was downgraded by analysts at ValuEngine from a sell rating to a strong sell rating. Align Technology (NASDAQ:ALGN) was downgraded by analysts at BidaskClub from a buy rating to a […]
- 01/28/2020
|
Denali Therapeutics Announces Proposed Offering of Common Stock
- Denali Therapeutics Inc. (DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock. In addition, Denali Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.
- 01/27/2020
|
Franklin Electric boosts quarterly dividend 7% FELE
- Franklin Electric boosts quarterly dividend 7% FELE
- 01/27/2020
|
FX Action: The dollar
- FX Action: The dollar
- 01/27/2020
|
J&J CEO says he didn't read all asbestos in talc documents, Reuters reports JNJ
- J&J CEO says he didn't read all asbestos in talc documents, Reuters reports JNJ
- 01/27/2020
|
Fly Intel: Top five analyst upgrades MRO;DNLI;ELF;CMG;BIIB
- Fly Intel: Top five analyst upgrades MRO DNLI ELF CMG BIIB
- 01/27/2020
|
Dallas Fed Mfg Survey General Activity Index data reported
- Dallas Fed Mfg Survey General Activity Index data reported
- 01/27/2020
|
Canaccord likes Biogen in premarket analyst action
- Relmada Therapeutics (NASDAQ:RLMD) initiated with Buy rating and $75 (73% upside) price target at Jefferies.Biogen (NASDAQ:BIIB) upgraded to Buy with a $360 (29% upside) price target at Canaccord Genu
- 01/27/2020
|
Flagship Pioneering Announces Ohana Biosciences
- Flagship Pioneering, a unique life sciences innovation enterprise, today announced a first-in-category reproductive health company, Ohana Biosciences. Ohana is embarking on a fresh approach to the field of reproductive medicine with the creation of the industry's first sperm biology platform, a major
- 01/27/2020
|
Axsome (AXSM) Completes Patient Randomization in TRD Study
- Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
- 01/23/2020
|
Axsome (AXSM) Completes Patient Randomization in TRD Study
- Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
- 01/23/2020
|
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
- The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
- 01/22/2020
|
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
- The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
- 01/22/2020
|
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?
- Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- 01/15/2020
|
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
- LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease LRRK2.
- 01/14/2020
|
Denali Therapeutics (NASDAQ:DNLI) Is In A Strong Position To Grow Its Business
- We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- 12/31/2019
|
